The ROLE OF HERBAL ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF FUNGAL DISEASES: A SYSTEMATIC REVIEW

  • KUSUM KAUSHIK Department of Pharmaceutics, LR Institute of Pharmacy, Solan, Himachal Pradesh, India.
  • SHWETA AGARWAL Department of Pharmaceutics, LR Institute of Pharmacy, Solan, Himachal Pradesh, India.

Abstract

Nowadays, fungal infection of skin is one of the most common dermatological problems worldwide. It has been investigated that 40 million people suffer from fungal infections. Superficial and subcutaneous fungal infections affect the skin, keratinous tissues, and mucous membranes. The dermatophytic infections, superficial candidiasis of the mouth, skin, or genital tract and infections due to Malassezia, such as pityriasis versicolor and Malassezia folliculitis are the main afflicting conditions. Systemic fungal infections may be caused by either an opportunistic organism that infects an at-risk host or may be associated with a more invasive organism or may be endemic to a specific geographical area. The most frequently encountered pathogens are Candida albicans and Aspergillus spp. but other fungi such as non-albicans Candida spp. are increasingly important in causing systemic fungal infections. There are numerous antifungal agents used clinically to treat fungal infections, i.e., azoles, allylamines, echinocandins, griseofulvin, and flucytosine. The course to modern treatment has not been without its problems and complications, particularly the drug resistances. Phytochemistry of various plant species has indicated that the phytochemicals could be a better source of medicine as compared to synthetically produced drugs. Natural medicines from a plant origin are still used as therapeutic agents, especially for treating bacterial, fungal, viral, protozoal, helminthic infections, etc. This review focuses on the use of plant constituents to prevent fungal infections caused by various pathogens. Hence, it will be proved beneficial for the drug industries.

Keywords: Fungal infection,, Dermatophyte,, Pityriasis versicolor,, Pathogens,, Endemic,, Natural medicines.

References

1. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10.
2. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
3. Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis 1997;16:424-36.
4. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: Human fungal infections. Sci Transl Med 2012;4:165rv13.
5. Fidel PL Jr., Barousse M, Espinosa T, Ficarra M, Sturtevant J, Martin DH, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004;72:2939-46.
6. Byrnes EJ 3rd, Li W, Lewit Y, Ma H, Voelz K, Ren P, et al. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the Northwest United States. PLoS Pathog 2010;6:e1000850.
7. Talaviya S, Majmudar F. Recent developments in antifungal agents. Int J Pharm Pharm Sci 2012;4 Suppl 4:4-10.
8. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of tacrine: I. Identification of a suitable delivery vehicle. Int J Pharm 1995;114:75 83.
9. Magdum C, Naikwade N, Shah R. Preparation and evaluation of fluconazole topical microemulsion. J Pharm Res 2009;3:557-61.
10. Banerjee M, Ghosh A, Basak S. Comparative evaluation of efficacy and safety of topical fluconazole and clotrimazole in the treatment of tinea corporis. J Pak Assoc Dermatol 2012;22:342-9.
11. Gungor S, Erdal M, Aksu B. New formulation strategies in topical antifungal therapy. J Cosmet Dermatol Sci Appl 2013;3:56-65.
12. Chen SC, Sorrell TC. Antifungal agents. Med J Aust 2007;187:404-9.
13. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part I. J Am Acad Dermatol 1994;30:677-98.
14. Gupta AK, Sauder DN, Shear NH. Antifungal agents: An overview. Part II. J Am Acad Dermatol 1994;30:911-33.
15. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007;3:CD001434.
16. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NL, Correr CJ. Efficacy of topical antifungals in the treatment of dermatophytosis: A mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol 2013;149:341-9.
17. Ozçelik B, Aslan M, Orhan I, Karaoglu T. Antibacterial, antifungal, and antiviral activities of the lipophylic extracts of Pistacia vera. Microbiol Res 2005;160:159-64.
18. Detandt M, Nolard N. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995;38:509-13.
19. Canavan TN, Elewski BE. Identifying signs of tinea pedis: A key to understanding clinical variables. J Drugs Dermatol 2015;14:s42-7.
20. Evans EG. Tinea pedis: Clinical experience and efficacy of short treatment. Dermatology 1997;194 Suppl 1:3-6.
21. Braun-Falco O, Plewig G, Wolff HH, Winkelman RK. Dermatology. 2nd ed. Berlin, Heidelberg: Springer Verlag; 1991.
22. Arnold HL, Odom R, William J. Andrews’ Diseases of the Skin. 8th ed. Philadelphia: W.B. Saunders; 1990.
23. Semel JD, Goldin H. Association of athlete’s foot with cellulitis of the lower extremities: Diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996;23:1162-4.
24. Fuller LC, Barton RC, Mohd Mustapa MF, Proudfoot LE, Punjabi SP, Higgins EM. British association of dermatologists’ guidelines for the management of tinea capitis 2014. Br J Dermatol 2014;171:454-63.
25. Elewski BE. Tinea capitis: A current perspective. J Am Acad Dermatol 2000;42:1-20.
26. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: Clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000;42:217-24.
27. Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997;136:490-3.
28. Greer DL. Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995;34:521-4.
29. Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: Pathophysiology, detection, and treatment. PLoS Pathog 2015;11:e1004523.
30. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016;214:15-21.
31. Rios-Fabra A, Moreno AR, Istúriz RE. Fungal infection in Latin American countries. Infect Dis Clin North Am 1994;8:129-54.
32. Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens DA, Hostetler JS, Cloud G, et al. Treatment of sporotrichosis with itraconazole. NIAID mycoses study group. Am J Med 1993;95:279-85.
33. Chapman SW, Daniel CR 3rd. Cutaneous manifestations of fungal infection. Infect Dis Clin North Am 1994;8:879-910.
34. Lilic D, Cant AJ, Abinun M, Calvert JE, Spickett GP. Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL- 4, IL-6 and interferon-gamma (IFN-gamma) production. Clin Exp Immunol 1996;105:205-12.
35. Lilic D, Calvert JE, Cant AJ, Abinun M, Spickett GP. Chronic mucocutaneous candidiasis. II. Class and subclass of specific antibody responses in vivo and in vitro. Clin Exp Immunol 1996;105:213-9.
36. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999;78:123-38.
37. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007;20:133-63.
38. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;31:327-32.
39. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE participant group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis 1998;30:121-9.
40. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
41. Beck-Sagué C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National nosocomial infections surveillance system. J Infect Dis 1993;167:1247 51.
42. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-8.
43. Odds FC. Epidemiological shifts in opportunistic and nosocomial Candida infections: Mycological aspects. Int J Antimicrob Agents 1996;6:141-4.
44. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
45. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
46. Walsh TJ, Dixon DM. Nosocomial aspergillosis: Environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989;5:131-42.
47. Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: A 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996;23:82-90.
48. Ruggieri M, Polizzi A, Vitaliti MC, Magro G, Musumeci S. Fatal biphasic brainstem and spinal leptomeningitis with Cryptococcus neoformans in a non-immunocompromised child. Acta Paediatr 1999;88:671-4.
49. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K, et al. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20:611-6.
50. Sugar AM. Mucormycosis. Clin Infect Dis 1992;14 Suppl 1:S126-9.
51. Reingold AL, Lu XD, Plikaytis BD, Ajello L. Systemic mycoses in the United States, 1980-1982. J Med Vet Mycol 1986;24:433-6.
52. Klein BS, Vergeront JM, Davis JP. Epidemiologic aspects of blastomycosis, the enigmatic systemic mycosis. Semin Respir Infect 1986;1:29-39.
53. Kirkland TN, Fierer J. Coccidioidomycosis: A reemerging infectious disease. Emerg Infect Dis 1996;2:192-9.
54. Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: Review of 155 reported cases. Clin Infect Dis 1996;23:125 30.
55. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511.
56. Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect 1999;41:181-94.
57. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years’ experience at a cancer center and implications for management. Blood 1997;90:999 1008.
58. Marcon MJ, Powell DA. Epidemiology, diagnosis, and management of Malassezia furfur systemic infection. Diagn Microbiol Infect Dis 1987;7:161-75.
59. Mirsaeidi M, Motahari H, Taghizadeh Khamesi M, Sharifi A, Campos M, Schraufnagel DE. Climate change and respiratory infections. Ann Am Thorac Soc 2016;13:1223-30.
60. McTaggart LR, Brown EM, Richardson SE. Phylogeographic analysis of Blastomyces dermatitidis and Blastomyces gilchristii reveals an association with North American freshwater drainage basins. PLoS One 2016;11:e0159396.
61. Roy M, Benedict K, Deak E, Kirby MA, McNiel JT, Sickler CJ, et al. A large community outbreak of blastomycosis in Wisconsin with geographic and ethnic clustering. Clin Infect Dis 2013;57:655-62.
62. Wheat LJ, Conces D, Allen SD, Blue-Hnidy D, Loyd J. Pulmonary histoplasmosis syndromes: Recognition, diagnosis, and management. Semin Respir Crit Care Med 2004;25:129-44.
63. Benedict K, Derado G, Mody RK. Histoplasmosis-associated hospitalizations in the United States, 2001-2012. Open Forum Infect Dis 2016;3:ofv219.
64. Capone D, Wanke B, Monteiro PC, Lazéra MS, de Noronha Andrade G, do Valle AC, et al. Chronic pulmonary histoplasmosis in the state of Rio de Janeiro, Brazil. Mycopathologia 1999;145:75-9.
65. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Infectious diseases society of America: Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23.
66. Nicas M. A point-source outbreak of coccidioidomycosis among a highway construction crew. J Occup Environ Hyg 2018;15:57-62.
67. Crum N, Lamb C, Utz G, Amundson D, Wallace M. Coccidioidomycosis outbreak among united states navy SEALs training in a Coccidioides immitis-endemic area – coalinga, California. J Infect Dis 2002;186:865 8.
68. Petersen LR, Marshall SL, Barton-Dickson C, Hajjeh RA, Lindsley MD, Warnock DW, et al. Coccidioidomycosis among workers at an archeological site, Northeastern Utah. Emerg Infect Dis 2004;10:637-42.
69. Williams PL, Sable DL, Mendez P, Smyth LT. Symptomatic coccidioidomycosis following a severe natural dust storm. An outbreak at the Naval Air Station, Lemoore, Calif. Chest 1979;76:566-70.
70. Osaki T, Morishita H, Maeda H, Kamei K, Hoshino S, Kijima T, et al. Pulmonary coccidioidomycosis that formed a fungus ball with 8-years duration. Intern Med 2005;44:141-4.
71. Capone D, Marchiori E, Wanke B, Dantas KE, Cavalcanti MA, Deus Filho A, et al. Acute pulmonary coccidioidomycosis: CT findings from 15 patients. Br J Radiol 2008;81:721-4.
72. Shikanai-Yasuda MA, Mendes RP, Colombo AL, Queiroz-Telles F, Kono AS, Paniago AM, et al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop 2017;50:715-40.
73. Bethlem EP, Capone D, Maranhao B, Carvalho CR, Wanke B. Paracoccidioidomycosis. Curr Opin Pulm Med 1999;5:319-25.
74. Edeoga HO, Okwu DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. Afr J Biotech 2005;4:685-8.
75. Akinmo-Laudn AC, Ibukun EO, Afor E, Obuotor EM, Farombi EO. Phytochemical constituents and antioxidant activity of extracts from leaves of O. gratissimum. Sci Res Essays 2007;2:163-6.
76. Rout SP, Choudhary KA, Kar DM, Das L, Jain A. Plants in traditional medicinal system-future source of new drugs. Int J Pharm Pharm Sci 2009;1:1-23.
77. Di Santo R. Natural products as antifungal agents against clinically relevant pathogens. Nat Prod Rep 2010;27:1084-98.
78. Tomishima M, Ohki H, Yamada A, Maki K, Ikeda F. Novel echinocandin antifungals. Bioorg Med Chem Lett 2008;18:1474-7.
79. Abad MJ, Ansuategui M, Bermejo P. Active antifungal substances from natural sources. Arkivoc 2007;7:116-45.
80. Barrett D. From natural products to clinically useful antifungals. Biochim Biophys Acta 2002;1587:224-33.
81. Taha KF, EL-Hawary SS, EL-Hefnawy HM, Mabrouk MI, Sanad RA, Harriry MY. Formulation and assessment of a herbal hair cream against certain dermatophytes. Int J Pharm Pharm Sci 2016;8:167-73.
82. De Leo M, Braca A, De Tommasi N, Norscia I, Morelli I, Battinelli L, et al. Phenolic compounds from Baseonema acuminatum leaves: Isolation and antimicrobial activity. Planta Med 2004;70:841-6.
83. Rubio OC, Cuellar AC, Rojas N, Castro HV, Rastrelli L, Aquino R. A polyisoprenylated benzophenone from Cuban propolis. J Nat Prod 1999;62:1013-5.
84. Dharmaratne HR, Piyasena KG, Tennakoon SB. A geranylated biphenyl derivative from Garcinia malvgostana. Nat Prod Res 2005;19:239-43.
85. Nkunya MH, Makangara JJ, Jonker SA. Prenylindoles from Tanzanian monodora and Isolona species. Nat Prod Res 2004;18:253-8.
86. Lee DG, Park Y, Kim MR, Jung HJ, Seu YB, Hahm KS, et al. Anti-fungal effects of phenolic amides isolated from the root bark of Lycium chinense. Biotechnol Lett 2004;26:1125-30.
87. Perry NB, Brennan NJ. Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru. J Nat Prod 1997;60:623 6.
88. Tan RX, Lu H, Wolfender JL, Yu TT, Zheng WF, Yang L, et al. Mono- and sesquiterpenes and antifungal constituents from Artemisia species. Planta Med 1999;65:64-7.
89. Bylka W, Szaufer-Hajdrych M, Mat?awska I, Go?li?ska O. Antimicrobial activity of isocytisoside and extracts of Aquilegia vulgaris L. Lett Appl Microbiol 2004;39:93-7.
90. Rao MS, Duddeck H, Dembinski R. Isolation and structural elucidation of 3,4’,5,7-tetraacetyl quercetin from Adina cordifolia (Karam Ki Gaach). Fitoterapia 2002;73:353-5.
91. Meragelman TL, Tucker KD, McCloud TG, Cardellina JH 2nd, Shoemaker RH. Antifungal flavonoids from Hildegardia barteri. J Nat Prod 2005;68:1790-2.
92. Hunter MD, Hull LA. Variation in the concentration of phloridzin and phloretin in apple foliage. Phytochemistry 1993;34:1251-4.
93. De Campos MP, Cechinel Filho V, Da Silva RZ, Yunes RA, Zacchino S, Juarez S, et al. Evaluation of antifungal activity of Piper solmsianum C. DC. Var. solmsianum (Piperaceae). Biol Pharm Bull 2005;28:1527-30.
94. Jung HJ, Sung WS, Yeo SH, Kim HS, Lee IS, Woo ER, et al. Antifungal effect of amentoflavone derived from Selaginella tamariscina. Arch Pharm Res 2006;29:746-51.
95. Sunthitikawinsakul A, Kongkathip N, Kongkathip B, Phonnakhu S, Daly JW, Spande TF, et al. Coumarins and carbazoles from Clausena excavata exhibited antimycobacterial and antifungal activities. Planta Med 2003;69:155-7.
96. Carpinella MC, Ferrayoli CG, Palacios SM. Antifungal synergistic effect of scopoletin, a hydroxycoumarin isolated from Melia azedarach L. fruits. J Agric Food Chem 2005;53:2922-7.
97. Rahalison L, Benathan M, Monod M, Frenk E, Gupta MP, Solis PN, et al. Antifungal principles of Baccharis pedunculata. Planta Med 1995;61:360-2.
98. Kofinas C, Chinou I, Loukis A, Harvala C, Roussakis C, Maillard M, et al. Cytotoxic coumarins from the aerial parts of Tordylium apulum and their effects on a non-small-cell bronchial carcinoma line. Planta Med 1998;64:174-6.
99. Shanker KS, Kanjilal S, Rao BV, Kishore KH, Misra S, Prasad RB. Isolation and antimicrobial evaluation of isomeric hydroxy ketones in leaf cuticular waxes of Annona squamosa. Phytochem Anal 2007;18:7 12.
100. Binutu OA, Adesogan KE, Okogun JI. Antibacterial and antifungal compounds from Kigelia pinnata. Planta Med 1996;62:352-3.
101. Manojlovic NT, Solujic S, Sukdolak S, Milosev M. Antifungal activity of Rubia tinctorum, Rhamnus frangula and Caloplaca cerina. Fitoterapia 2005;76:244-6.
102. Escalante AM, Santecchia CB, López SN, Gattuso MA, Gutiérrez Ravelo A, Delle Monache F, et al. Isolation of antifungal saponins from Phytolacca tetramera, an Argentinean species in critic risk. J Ethnopharmacol 2002;82:29-34.
103. Du Z, Zhu N, Ze-Ren-Wang-Mu N, Shen Y. Two new antifungal saponins from the Tibetan herbal medicine Clematis tangutica. Planta Med 2003;69:547-51.
104. Sautour M, Miyamoto T, Lacaille-Dubois MA. Steroidal saponins from Smilax medica and their antifungal activity. J Nat Prod 2005;68:1489 93.
105. Xie BB, Liu HY, Ni W, Chen CX, Lü Y, Wu L, et al. Five new steroidal compounds from Ypsilandra thibetica. Chem Biodivers 2006;3:1211 8.
106. Larcher G, Morel C, Tronchin G, Landreau A, Séraphin D, Richomme P, et al. Investigation of the antifungal activity of caledonixanthone E and other xanthones against Aspergillus fumigatus. Planta Med 2004;70:569-71.
107. Joseph CC, Moshi MJ, Sempombe J, Nkunya MH. (4-methoxy-benzo[1,3]dioxol-5-Yl)-phenylmethanone: An antibacterial bnenzophenone from Securidaca longepedunculata. Afr J Trad CAM 2006;3:80-6.
108. Pinto DC, Fuzzati N, Pazmino XC, Hostettmann K. Xanthone and antifungal constituents from Monnina obtusifolia. Phytochemistry 1994;37:875-8.
109. Wang YH, Hou AJ, Zhu GF, Chen DF, Sun HD. Cytotoxic and antifungal isoprenylated xanthones and flavonoids from Cudrania fruticosa. Planta Med 2005;71:273-4.
110. Klausmeyer P, Chmurny GN, McCloud TG, Tucker KD, Shoemaker RH. A novel antimicrobial indolizinium alkaloid from Aniba panurensis. J Nat Prod 2004;67:1732-5.
111. Singh NV, Azmi S, Maurya S, Singh UP, Jha RN, Pandey VB. Two plant alkaloids isolated from Corydalis longipes as potential antifungal agents. Folia Microbiol (Praha) 2003;48:605-9.
112. Dabur R, Chhillar AK, Yadav V, Kamal PK, Gupta J, Sharma GL. In vitro antifungal activity of 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol- 2-yl)-1-methylethyl pentanoate, a dihydropyrrole derivative. J Med Microbiol 2005;54:549-52.
113. Morteza-Semnani K, Amin G, Shidfar MR, Hadizadeh H, Shafiee A. Antifungal activity of the methanolic extract and alkaloids of Glaucium oxylobum. Fitoterapia 2003;74:493-6.
114. Emile A, Waikedre J, Herrenknecht C, Fourneau C, Gantier JC, Hnawia E, et al. Bioassay-guided isolation of antifungal alkaloids from Melochia odorata. Phytother Res 2007;21:398-400.
115. Liu SC, Oguntimein B, Hufford CD, Clark AM. 3-methoxysampangine, a novel antifungal copyrine alkaloid from Cleistopholis patens. Antimicrob Agents Chemother 1990;34:529-33.
116. Rahman AU, Nasreen A, Akhtar F, Shekhani MS, Clardy J, Parvez M, et al. Antifungal diterpenoid alkaloids from Delphinium denudatum. J Nat Prod 1997;60:472-4.
117. Wang F, Yang D, Ren S, Zhang H, Li R. Chemical composition of essential oil from leaves of Litsea cubeba and its antifungal activities. Zhong Yao Cai 1999;22:400-2.
118. Marthanda Murthy M, Subramanyam M, Hima Bindu M, Annapurna J. Antimicrobial activity of clerodane diterpenoids from Polyalthia longifolia seeds. Fitoterapia 2005;76:336-9.
119. Portillo A, Vila R, Freixa B, Ferro E, Parella T, Casanova J, et al. Antifungal sesquiterpene from the root of Vernonanthura tweedieana. J Ethnopharmacol 2005;97:49-52.
120. Ye XY, Ng TB. Purification of angularin, a novel antifungal peptide from adzuki beans. J Pept Sci 2002;8:101-6.
121. Ye XY, Ng TB, Rao PF. Cicerin and arietin, novel chickpea peptides with different antifungal potencies. Peptides 2002;23:817-22.
122. Taira T, Toma N, Ishihara M. Purification, characterization, and antifungal activity of chitinases from pineapple (Ananas comosus) leaf. Biosci Biotechnol Biochem 2005;69:189-96.
Statistics
270 Views | 63 Downloads
How to Cite
KUSUM KAUSHIK, and SHWETA AGARWAL. “The ROLE OF HERBAL ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF FUNGAL DISEASES: A SYSTEMATIC REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 7, May 2019, pp. 34-40, https://innovareacademics.in/journals/index.php/ajpcr/article/view/33831.
Section
Review Article(s)